Indie Asset Partners LLC grew its position in Eli Lilly and Company (NYSE:LLY) by 0.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 69,033 shares of the company’s stock after buying an additional 340 shares during the period. Eli Lilly and comprises about 13.6% of Indie Asset Partners LLC’s portfolio, making the stock its biggest holding. Indie Asset Partners LLC’s holdings in Eli Lilly and were worth $11,656,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Crestwood Advisors Group LLC grew its position in shares of Eli Lilly and by 1,099.4% in the 4th quarter. Crestwood Advisors Group LLC now owns 37,266 shares of the company’s stock valued at $6,292,000 after acquiring an additional 34,159 shares during the period. Personal CFO Solutions LLC boosted its holdings in shares of Eli Lilly and by 31.3% during the 4th quarter. Personal CFO Solutions LLC now owns 2,125 shares of the company’s stock worth $359,000 after buying an additional 506 shares during the period. SeaCrest Wealth Management LLC boosted its holdings in shares of Eli Lilly and by 4.7% during the 4th quarter. SeaCrest Wealth Management LLC now owns 16,665 shares of the company’s stock worth $2,814,000 after buying an additional 755 shares during the period. Lord Abbett & CO. LLC bought a new stake in shares of Eli Lilly and during the 4th quarter worth about $92,322,000. Finally, Swedbank boosted its holdings in shares of Eli Lilly and by 29.4% during the 4th quarter. Swedbank now owns 747,933 shares of the company’s stock worth $124,912,000 after buying an additional 170,103 shares during the period. 75.59% of the stock is owned by institutional investors.
LLY has been the subject of several research analyst reports. Cowen lifted their target price on shares of Eli Lilly and from $195.00 to $235.00 and gave the stock an “outperform” rating in a report on Friday, February 12th. Morgan Stanley lifted their target price on shares of Eli Lilly and from $190.00 to $217.00 and gave the stock an “overweight” rating in a report on Thursday, February 4th. Bank of America lifted their target price on shares of Eli Lilly and from $195.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, January 22nd. Mizuho lifted their target price on shares of Eli Lilly and from $222.00 to $228.00 and gave the stock a “buy” rating in a report on Monday, February 1st. Finally, Sanford C. Bernstein assumed coverage on shares of Eli Lilly and in a report on Tuesday, November 10th. They issued a “market perform” rating and a $150.00 price objective for the company. Four investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $190.31.
NYSE:LLY traded up $0.88 on Tuesday, reaching $201.56. 56,785 shares of the company’s stock were exchanged, compared to its average volume of 4,843,328. The company has a debt-to-equity ratio of 3.27, a current ratio of 1.36 and a quick ratio of 1.06. The firm has a market cap of $193.18 billion, a price-to-earnings ratio of 32.79, a P/E/G ratio of 1.57 and a beta of 0.37. Eli Lilly and Company has a 52 week low of $117.06 and a 52 week high of $218.00. The stock has a fifty day simple moving average of $195.97 and a 200-day simple moving average of $161.62.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Thursday, January 28th. The company reported $2.75 earnings per share for the quarter, beating analysts’ consensus estimates of $2.35 by $0.40. The business had revenue of $7.44 billion for the quarter, compared to the consensus estimate of $7.27 billion. Eli Lilly and had a net margin of 24.01% and a return on equity of 166.45%. Eli Lilly and’s quarterly revenue was up 21.7% on a year-over-year basis. During the same period last year, the firm posted $1.73 earnings per share. As a group, sell-side analysts predict that Eli Lilly and Company will post 7.56 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 10th. Investors of record on Friday, February 12th will be paid a $0.85 dividend. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.74. This represents a $3.40 dividend on an annualized basis and a yield of 1.69%. The ex-dividend date of this dividend is Thursday, February 11th. Eli Lilly and’s dividend payout ratio (DPR) is currently 56.29%.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia.
Featured Article: Cost of Capital
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.